Atopic dermatitis (AD) is a chronic inflammatory skin disease characterized by recurrent eczematous lesions and sustained pruritus.
1 Due to its chronic and recurrent nature, patients with moderate to severe AD usually require long-term treatment. However, many available AD treatments, including high-potency topical corticosteroids (TCSs), topical calcineurin inhibitors (TCIs), systemic corticosteroids (SCSs), systemic immunosuppressants, and UV therapy, are typically not recommended for long-term use due to concerns around safety or lack of efficacy data.
2 Janus kinase inhibitors, which are also approved to treat moderate to severe AD, carry an increased risk of infections and cardiovascular events.
3